Transcranial Magnetic Stimulation Combined With Multimodality Aphasia Therapy for Chronic Poststroke Aphasia: A Randomized Clinical Trial.

Abstract

Intensive speech therapy may improve recovery from poststroke aphasia. Further evidence suggests that pairing repetitive transcranial magnetic stimulation (rTMS) with intensive speech therapy might augment outcomes. This sham-controlled randomized clinical trial evaluated the efficacy of 1-Hz rTMS over the right pars triangularis combined with multimodality aphasia therapy (M-MAT) in chronic poststroke aphasia. A parallel-group, double-blind, sham-controlled randomized clinical trial was conducted between April 2021 and May 2023 at an outpatient neurorehabilitation clinic. Individuals with chronic nonfluent aphasia after left middle cerebral artery stroke (>6 months from stroke) were enrolled and randomly assigned to receive either rTMS or sham stimulation combined with 35 hours of M-MAT over 10 days. The primary outcome was the Western Aphasia Battery aphasia quotient (WAB-AQ) measured at 3 weeks and 15 weeks. Intention-to-treat analysis examined treatment effects over time using linear mixed models. A total of 44 participants were randomized. Forty-three (mean [SD] age, 63.4 [12.3] years; 14 women [32.6%]) completed the intervention. Overall, WAB-AQ scores improved from baseline to 15 weeks regardless of rTMS allocation (mean difference 5.33, 95% CI 2.9-7.8, <i>p</i> < 0.001). We observed a significant group-by-time interaction (β = 0.31, <i>p</i> = 0.024), suggesting that those who received rTMS combined with M-MAT improved more over time than those who received sham. At 15 weeks, the rTMS group demonstrated significantly less word-finding difficulties and more complete and longer sentences with fewer pauses compared with sham as indicated by higher WAB-AQ scores (mean difference 4.1 points, 95% CI 0.6-7.6, <i>p</i> = 0.022). The change from baseline at 15 weeks was greater in the rTMS group (7.6 points, 95% CI 4.1-11.1) compared with sham (3.0 points, 95% CI -0.3 to 5.2; mean difference 4.6 points, 95% CI 0.6-8.6, <i>p</i> = 0.024). Intensive administration of M-MAT alone improves speech production in patients with chronic poststroke aphasia. Combining 1-Hz rTMS with M-MAT is associated with supplemental improvements in aphasia severity at follow-up. rTMS is a promising candidate as an adjuvant therapy to M-MAT. ClinicalTrials.gov Identifier: NCT04102228. This study provides Class III evidence that in patients with aphasia 6 or more months after a stroke, 1-Hz rTMS combined with intensive M-MAT improves WAB-AQ more than sham stimulation plus M-MAT.